A groundbreaking trial in the UK is testing the world’s first “personalized” mRNA vaccine against the deadliest form of skin cancer, melanoma. This innovative vaccine is tailored to each patient’s unique tumor genetics, directing the immune system to target and destroy cancer cells. The treatment, which trains the body to produce proteins or antibodies against specific cancer cell markers, is also under evaluation in other countries like Australia to determine its broader applicability.